Neumora Therapeutics

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019 by ARCH Venture Partners and headquartered in Watertown, Massachusetts. The company focuses on developing precision therapeutics for neuropsychiatric and neurodegenerative brain diseases, operating on the thesis that brain disorders require distinct molecular targets matched to specific patient subpopulations rather than broad pharmacological approaches. Neumora completed its Nasdaq IPO (ticker: NMRA) in September 2023 and raised over $500 million at launch, including a $100 million equity investment from Amgen.

Neuromora's precision data science platform is designed to cut through the heterogeneity of brain disease to identify targeted therapies for defined patient populations. The company's pipeline spans seven neuroscience programs targeting novel mechanisms of action across underserved conditions. In 2025, it prioritized obesity as the lead indication for its NLRP3 inhibitor (NMRA-215), expanded its M4 PAM franchise, and advanced NMRA-511.

The company suffered a significant setback when its lead candidate navacaprant failed all three Phase III trials (KOASTAL-1, -2, and -3) in major depressive disorder, leading to navacaprant's discontinuation and a ~35% workforce reduction. Neumora is now pivoting its active portfolio toward Alzheimer's agitation, schizophrenia, and obesity, with cash runway guided into Q3 2027. Paul L. Berns, a co-founder and ARCH Managing Director, serves as CEO and Chairman as of February 2025.